



Tenofovir (maleate)

Catalog No: tcsc1875

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Specifications
CAS No: 1236287-04-9
Formula: C ₁₃ H ₁₈ N ₅ O ₈ P
Pathway: Anti-infection;Anti-infection
Target: Reverse Transcriptase;HIV
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: GS 1278 maleate;PMPA maleate;TDF maleate
Observed Molecular Weight: 403.28

Product Description





Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

In Vitro: Tenofovir shows cytotoxic effects on cell viability in HK-2 cells, with IC $_{50}$ values of 9.21 and 2.77 μ M at 48 and 72 h in MTT assay, respectively. Tenofovir diminishes ATP levels in HK-2 cells. Tenofovir (3.0 to 28.8 μ M) increases oxidative stress and protein carbonylation in HK-2 cells. Furthermore, Tenofovir induces apoptosis in HK-2 cells, and that apoptosis is induced via mitochondrial damage^[1]. Tenofovir and M48U1 formulated in 0.25% HEC each inhibits the replication of both R5-tropic HIV-1_{BaL} and X4-tropic HIV-1_{IIIb} in activated PBMCs, and inhibits several laboratory strains and patient-derived HIV-1 isolates. The combined formulation of M48U1 and tenofovir in 0.25% HEC exhibits synergistic antiretroviral activity against infection with R5-tropic HIV-1_{BaL}, and is not toxic to PBMCs^[2].

In Vivo: Tenofovir Disoproxil Fumarate (20, 50, 140, or 300 mg/kg) administered to BLT mice, shows dose dependent activity during vaginal HIV challenge in BLT humanized mice. Tenofovir Disoproxil Fumarate (50, 140, 300 mg/kg) significantly reduces HIV transmission in BLT mice^[3]. Tenofovir Disoproxil Fumarate (0.5, 1.5, or 5.0 mg/kg/day, p.o.) induces a dose-dependent decline in serum viremia in woodchucks chronically infected with WHV. Tenofovir Disoproxil Fumarate administration is safe and effective in the woodchuck model of chronic HBV infection^[4].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!